All Stories

  1. Predictive, preventive, and personalized medicine for respiratory viral infections: Integration of mechanistic insights and precision interventions
  2. Prevalence of RSV among patients in tertiary hospitals and healthcare worker knowledge in The Gambia: A paradigm shift from reactive to proactive 3PM-guided care is envisaged
  3. Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
  4. Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers
  5. Molecular Medicine - New Insights
  6. What does one-dimensional gel electrophoresis-based western blotting data really mean in the reality of proteoforms?
  7. Glioma angiogenesis phosphoproteome landscape and biomarker sets identified with phenome-centered multiomics toward 3P medical approaches
  8. The use of predictive, preventive, and personalized medical approaches to optimize hypertension management
  9. Proteoformics: Current status and future perspectives
  10. Mitochondrial medicine: “from bench to bedside” 3PM-guided concept
  11. Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management
  12. Pyruvate Kinase M1/2 Proteoformics for Accurate Insights into Energy Metabolism Abnormity to Promote the Overall Management of Ovarian Cancer Towards Predictive, Preventive, and Personalized Medicine Approaches
  13. Multiomics as instrument to promote 3P medical approaches for the overall management of respiratory syncytial viral infections
  14. Big data for neuroscience in the context of predictive, preventive, and personalized medicine
  15. Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches
  16. Editorial: Biomolecular modifications in endocrine-related cancers, volume II
  17. Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged
  18. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach
  19. Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach
  20. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine
  21. Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach
  22. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics
  23. Modifications in Biomacromolecules
  24. Personalized Medicine - New Perspectives
  25. Editorial: Advances in approaches for function-preserving gastric cancer surgery
  26. Nitroproteomics is instrumental for stratification and targeted treatments of astrocytoma patients: expert recommendations for advanced 3PM approach with improved individual outcomes
  27. The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer
  28. Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach
  29. Ubiquitinomics revealed disease- and stage-specific patterns relevant for the 3PM approach in human sigmoid colon cancers
  30. Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors
  31. Mass spectrometry analysis of phosphotyrosine‐containing proteins
  32. Editorial: New molecular targets involved in lung adenocarcinoma
  33. Significance of logistic regression scoring model based on natural killer cell-mediated cytotoxic pathway in the diagnosis of colon cancer
  34. Editorial: Biomolecular modifications in endocrine-related cancers
  35. A Powerful Paradigm: Predictive, Preventive, and Personalized Medicine with Multiomics of Human Pituitary Adenomas
  36. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis
  37. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine
  38. Ubiquitination-mediated molecular pathway alterations in human lung squamous cell carcinomas identified by quantitative ubiquitinomics
  39. The role of protein acetylation in carcinogenesis and targeted drug discovery
  40. Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine
  41. Tangled quest of post-COVID-19 infection-caused neuropathology and what 3P nano-bio-medicine can solve?
  42. Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine
  43. The comparison between 2DE‐MS and bottom‐up LC‐MS demands high‐end techniques for both technologies
  44. Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine
  45. Machine Learning Identifies Pan‐Cancer Landscape of Nrf2 Oxidative Stress Response Pathway‐Related Genes
  46. Mitochondrial Dysfunction Pathway Alterations Offer Potential Biomarkers and Therapeutic Targets for Ovarian Cancer
  47. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine
  48. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
  49. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
  50. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors
  51. Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine
  52. Introductory Chapter: Metabolomics
  53. Metabolomics - Methodology and Applications in Medical Sciences and Life Sciences
  54. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics
  55. The use of mass spectrometry in a proteome‐centered multiomics study of human pituitary adenomas
  56. Targeting Nrf2-Mediated Oxidative Stress Response Signaling Pathways as New Therapeutic Strategy for Pituitary Adenomas
  57. Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches
  58. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas
  59. Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer
  60. The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer
  61. Cell Culture: Advanced Technology and Applications in Medical and Life Sciences [Working Title]
  62. Comprehensive Analysis of Alteration Landscape and Its Clinical Significance of Mitochondrial Energy Metabolism Pathway‐Related Genes in Lung Cancers
  63. HSP60 Regulates Lipid Metabolism in Human Ovarian Cancer
  64. Ubiquitin - Proteasome Pathway
  65. Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas
  66. SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells
  67. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine
  68. Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
  69. 10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020
  70. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas
  71. Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine
  72. Proteoforms - Concept and Applications in Medical Sciences
  73. Introductory Chapter: Proteoforms
  74. Prolactin Proteoform Pattern Changed in Human Pituitary Adenoma Relative to Control Pituitary Tissues
  75. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes
  76. EDITORIAL: A SPECIAL ISSUE DEDICATED TO THE PROFESSIONAL CONTRIBUTIONS OF DOMINIC M. DESIDERIO
  77. Mitochondrial Proteomic and Molecular Network Alterations in Human Ovarian Cancers
  78. Editorial: Molecular Network Study of Pituitary Adenomas
  79. MASS SPECTROMETRY‐BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS
  80. MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
  81. Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas
  82. Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas
  83. Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients
  84. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles
  85. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
  86. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
  87. Application of Two-Dimensional Gel Electrophoresis in Combination with Mass Spectrometry in the Study of Hormone Proteoforms
  88. Energy Metabolism Heterogeneity-Based Molecular Biomarkers for Ovarian Cancer
  89. Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level
  90. Invasiveness-Related Proteomic Variations and Molecular Network Changes in Human Nonfunctional Pituitary Adenomas
  91. Recognition of Multiomics-Based Molecule-Pattern Biomarker for Precise Prediction, Diagnosis, and Prognostic Assessment in Cancer
  92. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas
  93. Identification of clinical trait–related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer
  94. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics
  95. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas
  96. The differentially mitochondrial proteomic dataset in human ovarian cancer relative to control tissues
  97. Protein Tyrosine Nitration in Lung Cancer: Current Research Status and Future Perspectives
  98. The Use of Gel Electrophoresis and Mass Spectrometry to Identify Nitroproteins in Nervous System Tumors
  99. Exploration of variations in proteome and metabolome for predictive diagnostics and personalized treatment algorithms: Innovative approach and examples for potential clinical application
  100. Prolactin Variants in Human Pituitaries and Pituitary Adenomas Identified With Two-Dimensional Gel Electrophoresis and Mass Spectrometry
  101. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes
  102. Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
  103. The crucial role of multiomic approach in cancer research and clinically relevant outcomes
  104. Every 2D spot contains over 50 to several hundreds of proteins - revival of 2DE-LC/MS in proteomics
  105. Revival of 2DE-LC/MS in Proteomics and Its Potential for Large-Scale Study of Human Proteoforms
  106. EPMA World Congress: Traditional Forum in Predictive, Preventive and Personalised Medicine for Multi-Professional Consideration and Consolidation
  107. Pattern recognition for predictive, preventive, and personalized medicine in cancer
  108. Editorial: Systems Biological Aspects of Pituitary Tumors
  109. Human Pituitary Adenoma Proteomics: New Progresses and Perspectives
  110. Exploration of Molecular Network Variations in Different Subtypes of Human Non-functional Pituitary Adenomas
  111. Nitroproteins in Human Astrocytomas Discovered by Gel Electrophoresis and Tandem Mass Spectrometry
  112. Proteomic and functional profiles of a follicle-stimulating hormone positive human nonfunctional pituitary adenoma
  113. EPMA position paper in cancer: current overview and future perspectives
  114. BMC Bioinformatics reviewer acknowledgement 2014
  115. Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas
  116. Identification of the proteomic variations of invasive relative to noninvasive nonfunctional pituitary adenomas
  117. Annual acknowledgement of reviewers
  118. Multi-parameter systematic strategy opinion that predicts, prevents, and personalized treats a cancer
  119. Mass spectrometry analysis of nitrotyrosine‐containing proteins
  120. Mapping the interactome of overexpressed RAF kinase inhibitor protein in a gastric cancer cell line
  121. Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics
  122. Reviewer acknowledgement 2012
  123. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer
  124. Pituitary Adenoma Nitroproteomics: Current Status and Perspectives
  125. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis
  126. Identification of differentially expressed proteins in the spinal cord of neuropathic pain models with PKCgamma silence by proteomic analysis
  127. Proteomic and Bioinformatics Analyses of Mouse Liver Microsomes
  128. The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas
  129. Signaling pathway networks mined from human pituitary adenoma proteomics data
  130. MALDI-induced fragmentation of leucine enkephalin, nitro-Tyr-leucine enkaphalin, and d5-Phe-nitro-Tyr-leucine enkephalin
  131. Detection of Nitrotyrosine-Containing Proteins
  132. Mass Spectrometric Identification of In Vivo Nitrotyrosine Sites in the Human Pituitary Tumor Proteome
  133. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses
  134. The human pituitary proteome: clinical applications
  135. Linear ion-trap mass spectrometric characterization of human pituitary nitrotyrosine-containing proteins
  136. Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry
  137. Proteomics analysis of growth hormone isoforms in the human pituitary
  138. Comparative proteomics analysis of human pituitary adenomas: Current status and future perspectives
  139. The human pituitary nitroproteome: detection of nitrotyrosyl-proteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry
  140. Heterogeneity Analysis of the Human Pituitary Proteome
  141. Comparative proteomics analysis of human lung squamous carcinoma
  142. Differences in the spatial and quantitative reproducibility between two second-dimensional gel electrophoresis systems
  143. Spot volume vs. amount of protein loaded onto a gel: A detailed, statistical comparison of two gel electrophoresis systems
  144. A reference map of a human pituitary adenoma proteome
  145. Proteomics and Transcriptomics Analyses of Secretagogin Down-Regulation in Human Non-Functional Pituitary Adenomas